You just read:

FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology

News provided by

Halozyme Therapeutics, Inc.

Jun 22, 2017, 15:16 ET